Format

Send to

Choose Destination
Expert Opin Ther Targets. 2010 Mar;14(3):253-64. doi: 10.1517/14728220903551304.

Autoimmune diseases: MIF as a therapeutic target.

Author information

1
Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Meibergdreef 9, Amsterdam, Netherlands. d.e.greven@amc.uva.nl

Abstract

IMPORTANCE OF THE FIELD:

Autoimmune inflammatory diseases occur commonly in developed countries. The treatment of these diseases is usually non-curative and is aimed at suppressing inflammatory end-organ damage. Macrophage migration inhibitory factor (MIF) is a multipotent cytokine that has been implicated in the pathogenesis of numerous autoimmune inflammatory disorders. The selective targeting of MIF with either anti-MIF antibody or specific MIF antagonists may offer new therapeutic avenues for these diseases.

AREAS COVERED IN THIS REVIEW:

Our aim is to discuss MIF-directed therapies as a novel therapeutic approach. The review covers literature from the past 10 years.

WHAT THE READER WILL GAIN:

MIF inhibition has been shown to be efficacious in many experimental and pre-clinical studies of autoimmune inflammatory diseases. The close regulatory relationship between MIF and glucocorticoids makes therapeutic antagonism of MIF a potential steroid-sparing therapy in patients with refractory autoimmune diseases.

TAKE HOME MESSAGE:

We expect that MIF antagonism by either small-molecule- or antibody-based approaches will find wide application in the treatment of autoimmune inflammatory diseases. Such therapy also may be informed by the MIF genotype of affected patients.

PMID:
20148714
DOI:
10.1517/14728220903551304
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center